"Loading Stock Price & Valuation Data ..."
Unlock News Summary by Subscribing to iPick.ai Premium!
Ask anything related to CTNM. [ FAQ on what and how to ask] For non-CTNM questions, click the logo in the upper-right corner to return to the main page and ask there.
CEO:Mr. Carmine N. Stengone MBA, MS
Headquarter: 3565 General Atomics Court, Suite 200, San Diego, CA, United States, 92121
Industry: Biotechnology, Investment Track: Biotech - Oncology - China, Employees: 51
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.
My Watchlist
